Will sarcopenia preventative pharmacology ensure the long-term success of GLP-1-derived therapies?
Key claim: Preserving lean mass through sarcopenia-preventative pharmacology may be essential to ensure the long-term metabolic and functional success of GLP-1-derived weight loss therapies.
Abstract
No abstract available.
Why this matters
This review [expert-opinion] extends the GLP-1 longevity debate from weight reduction toward pharmacological muscle preservation, without providing media/community evidence that combination protocols are spreading. Its proposed necessity remains unproven [expert-opinion]: lean-mass changes alone do not establish sarcopenia, and the finding supplies no new primary evidence that adjunctive drugs preserve function, improve long-term metabolic outcomes, or are safe in combination.